A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

NCT00282386 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2586

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Adenoma

Interventions

DRUG: MK0966; Rofecoxib / Duration of Treatment: 156 weeks
DRUG: Placebo/ Duration of Treatment: 156 weeks

Sponsor

Merck Sharp & Dohme LLC